Introduction

C
ancer cells have augmented nutrient transport and metabolism to cope with their enhanced activities in cell proliferation and survival [1] . Upregulated nutrient transporters and metabolising enzymes provide potential targets for anticancer therapy and diagnosis. For instance, expression of glucose transporters GLUT (solute carrier SLC2A subfamily) and hexokinases is increased in most types of cancer. Both are targets of the glucose analogue 2-deoxy-2-[
18 F]fluoro-D-glucose ([ 18 F]FDG), the most frequently applied probe for tumour imaging by positron emission tomography (PET) [2] .
(SLC7A11), and ATB 0,+ (SLC4A16) are upregulated in many cancer types [1, 3] . Figure 1 shows an overview of their transport characteristics. The amino acid PET probes 6-[ 18 [1, [4] [5] [6] . Besides LAT, also ASCT2 and xCT are exchange transporters. The ASCT2 substrate [ 18 F]fluciclovine (anti-[ 18 F]FACBC), a leucine derivative which is currently under clinical investigation, shows promising characteristics for the imaging of aggressive prostate cancer [7, 8] . Among these transporters, only ATB 0,+ is unidirectional. It has the unique property to transport its substrates even against a concentration gradient from extra-to intracellular. While LAT, ASCT2 and xCT promote influx of neutral amino acids, ATB 0,+ recognises also cationic besides neutral amino acids [1] . ATB 0,+ overexpression has so far been shown in breast, colorectal and cervical cancers and cell lines of colon and breast cancer [1, 9] . Compared to other amino acid transport systems, it has relatively low expression levels in healthy tissue. Significant expression was detected in lung, trachea, salivary glands, mammary glands and pituitary gland and lower levels in colon, uterus, prostate and testis [10, 11] . ATB 0,+ is characterised by a broad substrate specificity, including D-amino acids. The unidirectional concentrative transport is driven by transmembrane gradients of sodium and chloride ions and more generally by the membrane potential [1, 12] . The transporter is currently under investigation as a drug target for cancer therapy. Inhibition of ATB 0,+ with α-methyl-DL-tryptophan (αMTRP), a LAT and ATB 0,+ inhibitor, resulted in reduction of xenograft size in nude mice in vivo and autophagy of tumour cells in vitro [9, 13] . Besides direct inhibition for anticancer therapy, the transporter may be targeted to deliver cytotoxic drugs into tumour cells. (EBSS, Invitrogen) [6] . For uptake studies, 20 kBq [ 18 F]FEMAET was added to each well or tube (time zero), and cells were incubated at the indicated temperature on a shaker at 25 rpm (PC-3) or 130 rpm (NCI-H69) and washed twice with ice cold incubation solution at the indicated time points. PC-3 cells were detached with 0.25 % trypsin/1 mM EDTA (Invitrogen); NCI-H69 cells were pelleted by centrifugation and radioactivity was quantified in a gamma counter and decaycorrected (Perkin Elmer Wizard 1480). Protein content of the lysed cells (2 % sodium dodecyl sulphate) was quantified in parallel with the DC Protein Assay (Bio-Rad) and bovine serum albumin as standard. For inhibition experiments, 10 mM (final concentration) 2-amino-2-norboranecarboxylic acid (BCH), 10 mM L-arginine, 10 mM L-lysine, 10 mM L-histidine (PC-3) or 1 mM αMTRP (NCI-H69) were added in 20 μL 100 mM phosphate buffer (all pH between 7.0 and 8.0) immediately before addition of the radiotracer.
For [
18 F]FEMAET efflux experiments, PC-3 cells were incubated with tracer as described above for 60 min and washed twice with ice cold EBSS before 400 μl EBSS containing 800 μM L-leucine, 10 mM L-lysine or the respective volume of EBSS (all pH between 7.0 and 8.0) was added (time zero). The plates were incubated at 37°C, and cells were washed twice with the respective ice cold incubation solution at the indicated time points, detached and analysed as described above.
Expression Levels of ATB 0,+ in Cultured Cells and Xenografts
Total RNA was isolated from PC-3, NCI-H69 and MDA-MB-231 (American Type Culture Collection) cell lines and the respective xenografts according to the protocols of the Isol-RNA Lysis Reagent (5 PRIME) and the bead-milling TissueLyser system (Qiagen). QuantiTect® Reverse Transcription Kit (Qiagen) was used to generate cDNA. The following primers (Microsynth) were used for the polymerase chain reaction (PCR): human beta-actin (ACTB), forward 5′-CATGTACGTTGCTATCCAGGC-3′, reverse 5′-CTCCTTAATGTCACGCACGAT-3′ and human ATB 0,+ (SLC6A14), forward 5′-TGGGGTCCATACCTGGAACA-3′, reverse 5′-TGCTGCCACTAACAGTAGGT-3′. Quantitation of ATB 0,+ expression was performed with the DyNAmoTM Flash SYBR® Green qPCR Kit (Thermo Scientific) using a 7900 HT Fast Real-Time PCR System (Applied Biosystems). The amplification signals were detected in real-time, which permitted accurate quantification of the amounts of the initial RNA template during 40 cycles according to the manufacturer's protocol. All reactions were performed in duplicates and within three independent runs. Quantitative analysis was performed using the SDS Software (v2.4) and a previously described 2 -ΔΔCt quantification method [15] . The specificity of the PCR products of each run was determined and verified with the SDS dissociation curve analysis feature.
PET with Xenograft-Bearing Mice
Animal care and experiments were conducted in compliance with Swiss Animal Welfare legislation and have been approved by the Veterinary Office of the Canton Zurich, Switzerland. Six weeks old female NMRI nu/nu mice from Charles River, Sulzfeld (Germany) were inoculated with 2×10 6 PC-3 cells in 0.1 ml PBS/matrigel 1:1 (Invitrogen; BP Biosciences) or 2×10 6 MDA-MB-231 cells in 0.1 ml matrigel subcutaneously on the right shoulder. For NCI-H69 xenografts, mice were inoculated with 10 7 NCI-H69 cells in 0.1 ml PBS subcutaneously on the right shoulder and 1 week later with the same cell number in matrigel on the left shoulder. Xenografts were grown for several weeks until they reached 0.5 to 1.5 cm 3 . Mice had free access to food and water. For dynamic scans from 1 to 90 min post injection (p.i.), one mouse with a PC-3 and one with an MDA-MB-231 xenograft were injected under anaesthesia (2-3 % isoflurane in oxygen/air) with 13 and 15 MBq [
18 F]FEMAET, respectively, in 0.1 ml formulation into a tail vein and a dynamic PET scan (Vista eXplore, Sedecal, Spain, axial field of view 4.8 cm) was started about 1 min later. For dynamic scans from 60 to 150 min (one mouse each with a PC-3 and MDA-MB-231 xenograft) and static scans from 60 to 90 min (six NCI-H69 xenograft-bearing mice for the inhibition study with αMTRP), mice were injected awake in a restraining tube with 5.6 to 14 MBq Control animals were injected the same volume vehicle only. During all scans, respiratory rate and body temperature were monitored and controlled between 50 and 70 beats per minute and 36 and 37°C by adjusting the isoflurane dose and with 37°C warm air, respectively. The PET scans were followed by a CT for anatomical orientation. PET data was reconstructed by 2-dimensional ordered subsets expectation maximisation and analysed with PMOD 3.4 (PMOD, Zürich, Switzerland). Volumes of interest (VOI) were delineated with help of the CT and PET images and standardised uptake values (SUV) were calculated for the VOIs as the ratio of regional averaged radioactivity in becquerel per cubic centimetre and injected radioactivity in becquerel per gram body weight. Radioactivity was decay-corrected for all calculations. SUV ratios in the inhibition study with αMTRP were compared by a two-tailed homoscedastic t test.
Results
Cell Uptake and Efflux Studies
As a cationic amino acid, [ 18 F]FEMAET may be transported by the exchange transporters CATs, y + LAT2 and b 0,+ AT or the concentrative transporter ATB 0,+ but not by LAT1/2 ( Fig. 1) Fig. 3a , 1 mM αMTRP inhibited uptake by 965 % at 37°C and to~30 % at 4°C after 30 min incubation, the time point when uptake at 37°C approached a plateau under identical experimental conditions [14] . Figure 3b shows [ 18 F]FEMAET accumulation in prostate cancer PC-3 cells at 37°C, reaching 8.8±1.6 % uptake per mg protein at 60 min (n =10). Uptake at 4°C was significantly lower with 1.9±1.0 %/mg. Figure 3c shows the effects of the (LAT1/2 and) ATB 0,+ inhibitor BCH [10, 16, 17] [6] . We expected that a selective ATB 0,+ substrate would not be recognised by exchange transporters. Extracellular amino acids should, therefore, not accelerate its efflux as tremendously as observed for the LAT1/2 substrates. As shown in Fig. 3e, f, both 
Expression of ATB 0,+ in NCI-H69, PC-3 and MDA-MB-231 Cells and Xenografts
As mentioned in the "Introduction", not all cancers overexpress ATB 0,+ . We confirmed expression of the transporter in both PC-3 and NCI-H69 cell lines by realtime PCR (Fig. 4) . As shown by Karunakaran et al. (Fig. 1) . Here, we provide strong evidence that [
18 F]FEMAET is selectively targeting the amino acid transporter ATB 0,+ , which is upregulated in several cancer types and is under investigation as a drug target for anticancer therapy [9] . As concluded from the relatively low uptake ratios between xenografts and reference tissue, [ 18 Further studies with transporter expression systems and/or targeted silencing of transporters with, e.g. siRNA will reveal the extent of contribution of alternative transport systems to [ 18 F]FEMAET cell uptake. We assign selectivity for ATB 0,+ transport to the following structure characteristics: (a) The tertiary amine of the amino acid side chain renders [ 18 F]FEMAET cationic at physiological pH with an expected pK a between 10 and 11 [20] . This impedes recognition by transport systems for neutral amino acids such as LAT. (b) ATB 0,+ has a less We modified tyrosine by ether coupling to the 5-hydroxy group rather than by an ester or amide bond at a carboxyl group as suggested for pro-drug design [11] . In contrast to pro-drugs, hydrolysis of the PET probe was not desired.
We are not aware of any other basic and cationic amino acid that is currently in use or under investigation for PET imaging. A promising new amino acid PET probe with a basic side chain, the triazole (S)-2-amino- [22] . Expression of ATB 0,+ is upregulated in oestrogensensitive breast cancer, in carcinoma of the cervix and colorectal cancer [9, 25, 26] . In addition, several oestrogen receptor positive cancer cell lines express ATB 0,+ [9, 13] . This is not surprising as the SLC6A14 (ATB 0,+ ) promoter contains several putative binding domains for the oestrogen receptors [9] . PC-3 cells as many other prostate cancer cells have high expression levels of the oestrogen receptors [27] . ATB 0,+ upregulation is, therefore, likely in these and other prostate cancer cells. We have confirmed its expression in the PC-3 cell line. Interestingly, we also found high expression in NCI-H69 cells which lack oestrogen, progesterone and androsterone receptors and have only low levels of glucocorticoid receptor [28] . This indicates that a high level of oestrogen receptor is not a prerequisite for ATB 0,+ overexpression. Besides oestrogen receptor-mediated induction, protein kinase C increases ATB 0,+ activity in cancer cells [29] . ATB 0,+ expression levels in most healthy tissues are relatively low [9, 25, 26] . This together with its concentrative transport mechanism and its broad substrate specificity makes ATB 0,+ a good target for anticancer therapy [9, 
